Buy Cipla, Lupin: Manoj Murlidharan

Manoj Murlidharan of Religare Securities told CNBC-TV18, "Pharma is a sector where we feel there can be movement because even yesterday IT and pharma had seen some buying. CNX Pharma is on the verge to break from the mean and we expect it to go to the first standard deviation, which is money can come in close to 6-8 percent on the sector itself." "Cipla is the top buy at Rs 710. We recommend it to buy with Rs 698 as stop loss and Rs 726 is what we expect the target would be. Lupin is also a buy at Rs 1724. The stop loss should be Rs 1,704 and we expect a target of Rs 1,766 on that," he said.